Back to company

CONTERA PHARMA A/S: Financial statements 2020

CVR: 33062214

CONTERA PHARMA A/S (CVR 33062214) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -9,724,551 and a net result of DKK -12,258,975 compared with DKK -2,002,844 the year before. Equity amounted to DKK 194,960,912. The solvency ratio was 96.8%. The company had 4 employees in the financial year.

Gross Profit
-9,724,551 kr.
Profit/Loss
-12,258,975 kr.
Equity
194,960,912 kr.
Total Assets
201,325,856 kr.
Employees
4

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2020--9.7 mio.-12.3 mio.195 mio.4
2019--1.2 mio.-2 mio.17.8 mio.1
2018-1.5 mio.-968 t.3.2 mio.2
2017-1.4 mio.-419 t.1 mio.2
2016-3.1 mio.866 t.1.5 mio.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is CONTERA PHARMA A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2020

Thomas Nikolaj Sager joins CONTERA PHARMA A/S as adm. dir.Dec 1, 2020

As of December 1, 2020, Thomas Nikolaj Sager is registered as adm. dir. of CONTERA PHARMA A/S.

John Bondo Hansen steps down as adm. dir. of CONTERA PHARMA A/SDec 1, 2020

As of December 1, 2020, John Bondo Hansen has stepped down as adm. dir. of CONTERA PHARMA A/S.

Eun Ju Kim joins the board of CONTERA PHARMA A/SNov 13, 2020

As of November 13, 2020, Eun Ju Kim has joined the board of directors of CONTERA PHARMA A/S.

Sang Hoon Kim leaves the board of CONTERA PHARMA A/SNov 13, 2020

As of November 13, 2020, Sang Hoon Kim has left the board of directors of CONTERA PHARMA A/S.

CONTERA PHARMA A/S: The 2019 annual report is outMay 22, 2020

CONTERA PHARMA A/S has published its annual report for 2019. Gross profit came to DKK -1,249,644, and the net result was DKK -2,002,844.

About CONTERA PHARMA A/S

CONTERA PHARMA A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CONTERA PHARMA ApS and CONCIT PHARMA ApS. The management consists of Thomas Nikolaj Sager. The company is owned by Bukwang Pharmaceutical Co., Ltd. The company has 1 employee. In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity amounted to DKK 79,471,802.